Clinical Trials Directory

Trials / Unknown

UnknownNCT05911698

Fractional co2 Laser Followed by Either Vitamin c or Tranexamic Acid in Treatment of Melasma.

Fractional co2 Laser Followed by Either Vitamin c or Tranexamic Acid in Treatment of Melasma. Asplit Face Dermoscopic and Clinical Study.

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
25 (estimated)
Sponsor
Khadija Qenawi · Academic / Other
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

The aim of the study: 1.To compare the efficacy and safety of fractional CO2 laser in combination with vitamin c and tranexamic acid in the treatment of melasma. 2 .To assess the value of dermoscope in measuring of the response to treatment in melasma patients compared to clinical scoring.

Detailed description

Melasma is a chronic dermatologic condition defined by hyperpigmented macules and patches that appear in areas of sun exposure . Traditionally, the mainstays of treatment for melasma have been topical bleaching agents and strict photoprotection. Additional adjuvant treatment modalities include chemical peels, dermabrasion, and laser treatments, all of which have demonstrated limited efficacy. There has been an interest in studying the effects of vitamin c and tranexamic acid in melasma. The development of fractional resurfacing has led to improvements to melasma treatment with decreased incidence of post-inflammatory hyperpigmentation; these improvements are due to the enhanced healing times and decreased inflammation as a result of the formation of microscopic columns of tissue destruction. These microscopic columns of damaged tissue are surrounded by areas of normal tissue, allowing for shorter migratory paths for the healing keratinocytes.

Conditions

Interventions

TypeNameDescription
DEVICEFractional co2 laserThe development of fractional resurfacing has led to improvements to melasma treatment with decreased incidence of post-inflammatory hyperpigmentation; these improvements are due to the enhanced healing times and decreased inflammation as a result of the formation of microscopic columns of tissue destruction. These microscopic columns of damaged tissue are surrounded by areas of normal tissue, allowing for shorter migratory paths for the healing keratinocytes.

Timeline

Start date
2023-10-28
Primary completion
2024-03-01
Completion
2024-03-01
First posted
2023-06-22
Last updated
2023-08-15

Source: ClinicalTrials.gov record NCT05911698. Inclusion in this directory is not an endorsement.